Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge

The use of immune-checkpoint inhibitor (ICI) therapy has significantly improved patient outcomes in a wide variety of cancers and has become a cornerstone in the treatment of renal cell carcinoma. However, ICI treatment has the potential to cause a variety of immune-related adverse events (irAEs) th...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarlotta, Matthew, Avery, Robin, Baraban, Ezra, Maleki, Zahra, Ged, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165714/
https://www.ncbi.nlm.nih.gov/pubmed/35669423
http://dx.doi.org/10.3389/fonc.2022.876797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165714/
https://www.ncbi.nlm.nih.gov/pubmed/35669423
http://dx.doi.org/10.3389/fonc.2022.876797

Ejemplares similares